pollakiuria and nycturia. Regarding the menopausal age we subdivided patients into 3 groups: group 1 -postmenopause from 1 to 5 years, group 2 -from 6 to 10 years, group 3 -over 11 years.
71.4% of patients complained of slight urinary incontinence. None of the selected patients had at any time previously undergone hormonal replacement therapy, nor were there contraindications to the treatment for them. The average height of the women under examination was 158 cm (range 145-170), average body weight was 63 Kg (range 45-83). The post-menopausal age was between 1 to over 11 years.
We applied estriol in the form of vaginal cream as follows:
one application of 4 g. of cream on seven consecutive evenings, two weekly applications in the subsequent three weeks, 7 days' suspension of treatment and then the treatment cycle recommenced for a total of fifteen weeks. Patients were assessed before and after treatment through history, objective urogynecologic examination, stress test, PC test, urinoculture and urodynamic examination (uroflowmetry, water cystomanometry, UPP).
RESULTS
On termination of treatment for the urgency/frequency syndrome, the outcome was positive (cured or improved) in 89.3% of cases, whereas urinary incontinence was reduced in 51% of cases (Table 1) .
We regard the cure as being the d i s a p p e a ra n c e of u rg e n c y , a daytime urination number below 7 and no more than one urination at night. Improvement is a reduction of symptoms compared to the start. Changes in urodynamic parameters are reported in Table 2 .
INTRODUCTION
The urethral syndrome characterized by urgency, frequency, dysuria, pain and suprapubic tenesmus, is the result of irritation of the thin urethral mucosa. In particular, urgency and frequency can be caused by atrophic thinning of the trigonum, which embryologically derives from estrogen-dependent tissue (1) (2). The purpose of our research was to assess the efficacy of a topical, vaginal, estrogen replacement treatment in women at menopausal age, suffering from urgency/frequency syndrome with unknown etiology.
Therapeutic options in topical estrogen therapy include the use of: conjugated estrogens, promestriene or estriol. We adopted estriol which, contrary to the other steroids, is a natural female hormone with poor endometrial trophism and shorter lasting action, and thus does not give rise to uterine mucous proliferation with resulting inter-menstrual flow. Estriol is also "biologically" the weakest hormone. In fact, in order for it to achieve its biological effect the hormone-receptor complex must remain in the nucleus for a long time: estriol disappears from the nucleus more rapidly than the powerful estradiol (3). Nonetheless, system absorption of estriol can be obtained, even if applied vaginally, with a resulting sense of mammary tension and excessive production of cervical mucous.
MATERIALS AND METHODS
We selected 56 patients attending the Urodynamic Service at our Institute, aged between 47 and 74 years, in post-menopause for at least one year and suffering from urgency/frequency syndrome, After treatment the 1st urinary stimulus and urinary urge stimulation occur with greater bladder fill volumes; moreover the mean and maximum urinary flow increases, whereas post voiding residual volume decreases.
There are differences between the three post-menopausal age groups. The older the patient the higher the percentage of negative results (Tab. 3). In 2% of cases side-effects were observed i.e. mammary tension and itchiness (without mycetes) Tab.3.
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